The latest early trial data suggests that current daily HIV pill regimens could potentially be replaced with injections that slowly release medication for the virus over time. This new method has proven to be as successful as current treatment plans and could provide the same benefits in just six injections annually. Antiretroviral treatment suppresses the
The pharmaceutical company recently unveiled late stage data that shows their experimental two-drug regimen of its dolutegravir and Janssen Science’s rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients. The dolutegravir/rilpivirine combination treatment achieved non-inferior viral suppression at 48 weeks compared with a three- or four-drug regimen in both
Researchers have begun testing an HIV vaccine in efficacy trials for the first time in seven years, with the hope to provide at least partial immunity against the virus. The study (HVTN 702) is currently being conducted in South Africa to test an updated version of an experimental vaccine developed by researchers at the US
J&J and its scientific collaborators are investigating whether changing the formulation of the vaccine antigens during the regimen – a ‘heterologous prime boost’ – can improve immune responses. After encouraging results in non-human primates for HIV vaccines, Johnson & Johnson (J&J) have now started enrolling volunteers.
diagnosis Tivicay, Launched in the UK” src=”http://i57.tinypic.com/2re6t69.jpg” width=”164″ height=”147″ />HIV patients in the UK will from this week have another treatment option after ViiV Healthcare announced the launch of their once-daily drug, Tivicay (dolutegravir). The integrase inhibitor was approved in Europe last month for HIV-1 in a broad patient population of treatment-naive and treatment-experienced adults